Figures & data
Table 1.
Summary of clinical studies conducted with cat allergen.
Table 2.
Four Phase II prospective, randomized, double-blind, placebo-controlled studies are summarized.
Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013;131:103-9 Hafner R, Couroux P, Armstrong K, et al. Two Year Persistent Treatment Effect Achieved After 4 Doses of Cat-Peptide Antigen Desensitization (Cat-PAD) in an Environmental Exposure Chamber (EEC) Model of Cat Allergy. J Allergy Clin Immunol 2013;131:AB147 Varney VA, Edwards J, Tabbah K, et al. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997;27:860-7 Berkowitz RB, Braker S, Lutz C, et al. Efficacy of fexofenadine in the prophylactic control of cat allergen-induced allergic rhinitis. Ann Allergy Asthma Immunol 2006;96:327-33 Patel D, Bernstein DL, Plunkett G, et al. Tolerability and efficacy of sublingual immunotherapy in cat allergic subjects studies in an environmental exposure chamber. Ann Allergy Asthma Immunol 2011;107:A105 Alexander C, Ying S, Kay AB, Larché M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 2005;35:52-8 Haumann B, Powell J, Hafner R. Safety and Tolerability of Fel d 1-Derived Peptide Antigen Desensitization. J Allergy Clin Immunol 2013;131:AB38